Abstract
Background
Multiple-system atrophy is a neurologic disorder characterized by orthostatic hypotension,
Parkinsonian signs, and cerebellar signs. Mutations in COQ2, an enzyme involved in
coenzyme Q10 synthesis, were recently associated with familial and sporadic cases
of multiple-system atrophy. I hypothesized that people with orthostatic hypotension
with or without other symptoms of multiple-system atrophy might benefit from oral
coenzyme Q10 administration.
Methods
Seven patients with symptomatic orthostatic hypotension were treated in an unrandomized
manner with 257 ± 37 mg coenzyme Q10 daily for 10 ± 3 months.
Results
Before starting coenzyme Q10, patients' systolic blood pressure fell 30 ± 4 mm Hg
upon standing from a sitting position. After treatment with coenzyme Q10, their systolic
blood pressure decreased 7 ± 5 mm Hg upon standing from a sitting position (P = .007 for change in systolic blood pressure decrease by paired t test).
Conclusions
These data suggest that orthostatic hypotension could improve with coenzyme Q10 administration
and that a randomized clinical trial to test this hypothesis should be begun.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.J Am Coll Cardiol. 2005; 45: 1243-1248
- Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy.J Neurol Neurosurg Psychiatry. 1969; 32: 28-34
- Mutations in COQ2 in familial and sporadic multiple-system atrophy.N Engl J Med. 2014; 369: 233-244
- Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.Neurology. 2005; 65: 1834-1836
Article Info
Publication History
Published online: October 25, 2017
Footnotes
Funding: None.
Conflict of Interests: None.
Authorship: The author had access to the data and played a role in writing this manuscript.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
